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ABSTRACT
The manifestation of multidrug resistance in bacteria over the past several decades has
resulted in one of the foremost challenges in the management of infectious diseases. The
question arises, “How do we address this growing problem?” One solution to stem the
growing rise in antimicrobial resistance is to investigate new targets, while another approach
is to re-examine classical antibacterial targets with a fresh perspective. The aim of this paper
is to begin the process of antibacterial development for the pathogen Clostridium difficile by
characterizing the cell wall acting glucosaminidase CD1034. It is inunderstanding how
CD1034 functions biochemically that it can be targeted for antibacterial development. The
gene CD1034 was successfully cloned and sequenced in this project. Results have
implications in the further development of an antibiotic for C. difficile and other Grampositive pathogens.
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INTRODUCTION
Hospitals today are ridden with disease, whether it is from the patients entering to be
treated or the dormant bacteria loitering within. Nosocomial infections are defined by the
World Health Organization (WHO) as infections acquired by a patient who was admitted for
reasons other than that infection (World Health Organization Department of Communicable
Disease, Surveillance and Response, 2002). These infections are prevalent world-wide, from
hospitals in developing nations to countries such as the United States. In this study by WHO,
it was found that nosocomial infections were most common at the sites of surgical wounds, in
the urinary tract, and in the lower respiratory tract. Nosocomial infections are one of the
leading causes of death in hospitals, and can also lead to a reduction in the quality of life of
patients due to excess stress and emotions from the infection. Many of these bacterial
infections are becoming larger problems due to the bacteria’s resistance to antibiotics.
Antibiotic resistance in a particular bacterium can happen in a few different ways. If
the bacterium is constantly being exposed to a specific type of antibiotic treatment, there are
ways in which it is able to adapt to not be affected by that treatment. This can happen in one
of two ways. The first is through the mutation of chromosomes, which is extremely rare. The
second method, which is far more common, is through a method called transmissible drug
resistance, or TRD for short (Black's Veterinary Dictionary, 2005). This is a method where
bacteria that carry what are known as R factors (resistance factors) in their cytoplasm are able
to pass the R factors on to other bacteria via contact. The R factors are transferred through
amedium called plasmids. This most commonly happens between bacteria that occupy the
intestinal tracts of humans, and usually occurs when the person who is hosting the bacteria is
receiving antibiotics for another infection. When that patient receives antibiotics, it disrupts
the normal colonic flora and makes the conditions perfect for the R factor transfer. This can
cause a patient who is already infected to become infected with a new bacterium, one which is
antibiotic resistant.
One particular type of bacteria that is becoming particularly troublesome in hospitals
is Clostridium difficile (C. difficile). C. difficileis a gram-positive organism, which means that
the cell wall is made of a thick layer of peptidoglycans. This bacterium currently has no easy
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and effective treatment, and has not responded to any type of antibiotics thus far. C. difficile is
a fecal organism that is rampant in hospitals and the major cause of hospital acquired cases of
diarrhea (Youngson, 2005). C. difficile targets those patients in a hospital that are at the
highest risk for nosocomial infections. These are the elderly patients, those who are
immunocompromised, and those who are on antibiotic regiments. Those who are on
antibiotics are at risk because the antibiotics disrupt the normal bacteria of the bowel,
allowing the bacterium to become well-established in the colon and intestines (Webster's New
World Medical Dictionary). Those who are elderly and immunocompromised are at risk of
non-normal flora, which, as previously stated, is the height of when C. difficilewill establish
itself in the body. It is also a tough bacterial infection to fight because some patients show
symptoms of infection rather quickly, while others do not show them whatsoever and become
what is known as a “carrier.” These carriers are dangerous because C. difficile is a sporeproducing bacterium and can quickly and easily spread from the carriers to the new victims.
The ability of the bacterium to produce spores, create carriers within the hospital
environment, and infect and re-infect those patients at the highest risk are the main reasons
why the spread of C. difficilehas significantly increased over the past decade (Wheeldon,
Worthington, Hilton, Elliott, & Lambert, 2008). Figure 1 reveals infection rates for those
patients aged 65 and older since only 1996, as shown in a study by the Centers for Disease
Control and Prevention.
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Figure 1 – Infection Rates of C. difficile in US Hospitals from 1996 – 2009
The figure shows increases in infection rates of 175% for those aged 65 – 74 years old, 198%
for those aged 75 – 84, and 201% for those aged ≥85 years of age. A total infection rate
increase of 200% for all patients aged ≥65 was found in this study as well. This is an
enormous increase from 1996 alone, never mind from decades prior. This study by the CDC
confirms prior studies that the elderly are at a higher risk of infection as well(Centers for
Disease Control and Prevention, 2011).
C. difficile is not only a major problem for patients in the hospital, but also to the
hospital itself.Hospitals are at risk of becoming subject to extremely high treatment costs
when looking into infections caused by C. difficile. Average daily costs for treating infections
causes by C. difficile ranges from 17.6 – 51.5 million dollars (Stabler, 2009). The range of
costs for first-time infected patients is $2,871 - $4,846 per case and $13,655 - $18,067 per
case for those patients who are re-infected (Ghantoji, Sail, Lairson, DuPont, & Garey, 2010).
This leads to costs in excess of $1 billion in the US annually. These numbers are staggering,
and are far too high for hospitals struggling to control costs. The need for an antimicrobial
now is extremely high. According to Herbert Dupont, other researchers are in the field
looking to develop a way to inhibit the infection process, much like this project intends to do.
However, some of those projects are looking to develop a way to restore or preserve the
colonic flora while taking antibiotics (Dupont, 2011). This approach is new and innovative,
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much like the approach this project takes on to inhibit the cell wall adhesion process of C.
difficile to the intestine wall.
This project will focus on the beginning stages of antimicrobial development for C.
difficile, more specifically the cloning and characterization of the cell wall acting enzyme
CD1034. CD1034 is a glucosaminidase specific to C. difficile, however has homologs in other
Gram-positive pathogens, which will lead to outside applications of the results. A
glucosaminidase is an enzyme which has the ability to hydrolyze peptidoglycans, which
means that CD1034 cleaves the glycosidic bond via the addition of water. This is very
important due to the fact that C. difficileis gram-positive with that thick layer of
peptidoglycans in its cell wall. From this, it is hypothesized that CD1034 is annotated in the in
the C. difficile genome to act on bacterial peptidoglycan as a β-glucosaminidase with the
ability to cleave peptidoglycans. Overall, this project seeks to begin the discovery process of
potential proteins that will be able to be developed further into methods of preventing or
stopping the infection process of C. difficile. The lab work, data collected, and further analysis
and conclusions that will be developed over the course of this Senior Capstone will help all
further researchers in taking this project a step further into developing an antimicrobial
against C. difficile.
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METHODS AND MATERIALS
Getting to Know the Lab
The first week of work for this Capstone began with learning more about the equipment I
would be using daily throughout the course of the experimentation. A sample of the
equipment I learned about this beginning week is:
1. Pipets (used to measure out small amounts of chemicals for solutions and can be easily
misued),
2. Autoclave (used to sterilize equipment such as flasks in a high pressure/high heat
environment for use in experimentation),
3. Polymerase chain reaction machine, and
4. Gel electrophoresis (used to run the polymerase chain reaction solutions in to check
for success in the reaction against a base).
This first week of learning about the equipment to be used was crucial for the success of the
remainder of the project.
PCRof CD1034 with AccuTaq Polymerase
A 50x TAE buffer was first made for the gel electrophoresis stage of this step. This buffer
was a solution of Trizma base, glacial acetic acid, EDTA, and deionized water. With this
buffer made, the first of three polymerase chain reactions (PCR) was set up. The purpose of
this reaction is to amplify the CD1034 gene, the cell wall acting enzyme that is strongly
thought to be involved in Clostridium difficilegrowth and division. The reagents of the
reaction included genomic DNA Cd630, which is the DNA of C. difficile that contains the
gene CD1034. The Sigma AccuTaq PCR Kit was used for this reaction, which utilizes taq
polymerase. Taq polymerase is one of the more cost-effective and commonly used
polymerases on the market. The DNA primer AV-1 was used as the forward primer and has
the sequence:
5’ – AAGACCCCATATGGCTAGAAAATTAATAAAAAATTTGGG – 3’
This forward primer is specifically engineered with an NdeI restriction site for cloning into
the plasmid pET28. The reverse primer AV-3 was used with the sequence:
5’ – TCTCGAGTTATTTTGTCTCAACTTTATTATCTATC – 3’
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This reverse primer was also engineered specifically with an XhoI restriction site for cloning
into the plasmid pET28. The conditions of the first PCR can be found in Table 1.
Table 1 – Conditions of the PCR of CD1034 with AccuTaq Polymerase

Denaturing

Extension Sit Stage

Annealing

98º C

94º C

55º C

68º C

68º C

4º C

48 sec.

20 sec.

20 sec.

1 min.

10 min.

Infinite

The reaction was analyzed in a 1% agarose gel electrophoresis, which is a scientific technique
that separates a population of DNA by size. This step is crucial in determining if the PCR was
successful in replicating the CD1034 portion of the genomic DNA. A GeneRuler 1 kb ladder
was placed into the first lane of the gel and the reaction was placed into the second lane of the
gel. The GeneRuler ladder is run against the reaction because the section of the DNA that is
expected to show on the gel (it will be a thick stain if the DNA was replicated because the
DNA is separated by size and amount) is approximately 1000 bases from the start of the
strand.
Effect of MgCl2on PCR of CD1034 withAccuTaq Polymerase
A second PCR was performed to amplify CD1034. The same genomic DNA, PCR kit, and
forward and reverse primers were used as from the first PCR, however additional magnesium
chloride (MgCl2) was added in different levels to this reaction. The first reaction contained an
additional 0.5 µL (microliters) of MgCl2. The second reaction contained an additional 1 µL of
MgCl2. The third reaction contained an additional 1.5 µL of MgCl2. Finally, the fourth
reaction contained an additional 2 µL of MgCl2. These four concentrations of MgCl2 were
added to try to find the ideal conditions in which the PCR would run. The conditions of the
PCR can be seen in Table 2. The gel was run on these four PCR products, with the GeneRuler
in the first lane, the four different reactions mentioned above in lanes 2-5 (respectively) and
the genomic DNA in lane 6.
Table 2 –Conditions of the PCR of CD1034 with AccuTaq Polymerase & Addition of MgCl2

Denaturing

Extension Sit Stage

Annealing

98º C

94º C

50º C

68º C

68º C

4º C

48 sec.

20 sec.

20 sec.

1 min.

10 min.

Infinite
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PCR of CD1034 with 5 Prime PCR Extender System
The third attempt at amplifying CD1034 was taken in a different direction. The 5 Prime PCR
Extender System was used in place of the Sigma AccuTaq PCR Kit, in addition to the same
genomic DNA and primers as stated in previous reactions. The 5 Prime PCR Extender System
includes a polymerase that is a blend of thermostable DNA polymerases with a processivityenhancing factor that provides a high extension rate and maximal proofreading capability and
also two different types of buffer – tuning buffer and high fidelity buffer. Four reactions were
developed for this PCR, two reactions with tuning buffer and two reactions with high fidelity
buffer. The two reactions for each buffer included different levels of genomic DNA Cd630 as
to find the optimal level. The conditions of the PCR can be seen in Table 3. The gel was run
with the following lanes:
1. GeneRuler 1 kb ladder
2. Tuning Buffer with Mg with 1.25 µL of genomic DNA CD630
3. Tuning Buffer with Mg with 2.5 µL of genomic DNA CD630
4. High Fidelity Buffer with Mg with 1.25 µL of genomic DNA CD630
5. High Fidelity Buffer with Mg with 2.5 µL of genomic DNA CD630.
Table 3 – Conditions of the PCR using the 5 Prime PCR Extender System

Annealing

Denaturing

Extension Sit Stage

93º C

93º C

55º C

68º C

68º C

12º C

2 min.

30 sec.

45 sec.

1 min.

10 min.

Infinite

Clean-up of PCR Reactions
The successful polymerase chain reaction solution must be cleaned up before any further
experimentation can take place. A cleanup of this reaction was performed using a Sigma
GenElute PCR Cleanup Kit. This cleanup was performed to rid the solution of any excess
nucleotides that were not used in the reaction, excess primers, and other excess material from
the PCR. The manufacturer’s instructions were followed to clean up the successful PCR
solution. First, DNA is bound on a silica membrane within the spin column. The DNA bound
to the column is washed and the clean DNA is eluted in buffer. This purifies and recovers
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approximately 95% of PCR product and more than 99% of primers and primer-dimers are
removed, leaving product ready for further experimentation.
Isolation of Plasmids
pET28 is the plasmid that is to be used for the purposes of this project. This particular plasmid
was propagated from Escherichia coli DH5α competent cells. The plasmids were prepared
using a Sigma GenElute Plasmid MiniPrep Kit. The manufacturer’s instructions were
followed to prepare the plasmids. The cells were first harvested from recombinant E. coli.
Next, the cultured cells were re-suspended in a re-suspension solution and from here they
were lysed by the addition of a Lysis Solution. The solution was mixed by means of gentle
inversion as to prevent the shearing of genomic DNA. The cells are then neutralized and
gently inverted again, and this solution is then transferred to a binding column. The elution is
performed, and thus the DNA is now present in the eluate and ready for experimentation.
RestrictionDigest of CD1034 & pET28
CD1034 and pET28 were digested after being cleaned and prepared. The purpose of the
digestion process is to ensure that all DNA fragments that have been replicated are the same
size. The reagents for the digestion included 10 µL of nuclease-free H2O, 2 µL of 10x buffer,
6 µL of the successful PCR product, 6 µL of the vector (pET28 plasmid), and also 0.5 µL of
both NdeI and XhoI. The product of the restriction digest was placed on the hot block for
approximately one hour, and after that hour an addition 0.5 µL of both NdeI and XhoI were
added to the solution.
Ligation of CD1034 into pET28
The first ligation was begun with a double restriction site cut of the vector. The reagents in the
ligation included 2 µL of 10x buffer for T4 DNA ligase with 10 mM ATP, 10 µL of PCR
insert, 5 µL of vector, 1 µL of ligase, and 2 µL of sterilized H2O. The resulting solution was
plated and left to grow overnight in the incubator.
The second ligation was begun with individual cuts of both the promoter and terminator ends
of the vector, which would increase the accuracy of the cut to nearly 100%. Two trials with
individual cuts were made, and the reagents for these ligations can be seen in Table 4. Both
ligation products were plated and left to grow overnight in an incubator.
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Table 4 – Reaction Conditions for Ligations with Individual Restriction Site Cuts
10 ng Vector:60 ng Insert

10 ng Vector:120 ng Insert

Vector

0.8 µL

0.8 µL

Insert

1 µL

2 µL

10x Buffer

1 µL

1 µL

Ligase

0.5 µL

0.5 µL

H2O

6.7 µL

5.7 µL

Total Volume

10 µL

10 µL

Sequencing of Successful Ligation
The colonies of the successful ligation were sent to the Rhode Island Genomics and
Sequencing Center to be sequenced. The sequencing results were promptly sent back to
Bryant Labs to be further analyzed and discussed.
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RESULTS
Different attempts to amplify the gene CD1034 were made in the beginning stages of this
project. After three attempts, the polymerase chain reaction to amplify CD1034 was best
when using the 5 Prime PCR Extender Kit. The specific reaction using this kit that was
successful had the addition of the Tuning Buffer with magnesium to 1.25 microliters of
genomic DNA. With the addition of the magnesium, this adds a positively charged ion to the
reaction, thus helping the negatively charged genomic DNA to react differently. The results of
the first PCR with only AccuTaq polymerase can be seen in Appendix A. Appendix B shows
the results from the second PCR with the AccuTaq polymerase and addition of MgCl2.
Finally, Appendix C shows the gel electrophoresis results from the third and final PCR with
the 5 Prime PCR Extender System. These results show that lane 2 (lane assignments are from
left to right, starting at lane 1) of the agarose gel electrophoresis (the successful reaction) has
the stain at approximately the 1000 base pair line on the GeneRuler, thus confirming
successful amplification of the CD1034 gene from the PCR. The successful PCR reaction was
the one in which tuning buffer was used in combination with 1.25 25 µL of genomic DNA
Cd630.
After a successful polymerase chain reaction was completed, it was then found that ligation
was only successful when the cutting of the plasmid was performed in two separate steps –
the forward cut and the reverse cut. The attempts at DNA ligation were unsuccessful when a
more efficient and less accurate double cut were made, thus the extra step is necessary for
100% accuracy. A 12:1 ratioof PCR insert to vector was also found to be successful in
ligation.
Finally, the sequencing results revealed that the gene CD1034 was successfully transformed
into the plasmid, pET28. Appendix D shows the forward sequencing results, revealing a 99%
match of the gene sequenced check against the known sequence of CD1034. The 1% mistake
is a silent transformation and is irrelevant. Appendix E shows the reverse sequence of the
gene sequenced check against the known CD1034 sequence. This 99% match is also only off
by 1% again because of a silent transformation that is irrelevant and does not change the gene
itself.
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DISCUSSION
Understanding the steps of the polymerase chain reaction process are key to seeing why it is
possible to amplify a particular gene over a billion replications in just over 2 hours’ time. In
the denaturing stage, the DNA is brought to a high temperature to separate it into single
strands (in laymen’s terms, unzipping the DNA strand to its forward and reverse sequences).
After this stage, the annealing stage begins. The beginning of this stage cools the DNA to
allow for the primers to attach to their specific sites on the individual strands. The final stage,
extension, is when the polymerase used in the process attaches to the priming sites and
extends, or synthesizes, the strands into exact replications of the original DNA strands. This
cycle of three stages is repeated 25-30 times, and this will yield upwards of 1 billion
replications of the original strand of DNA if successful. The “sit” stage is not timed and is a
setting in the PCR machine to allow for a reaction to run without human supervision and be
ready to go when necessary.
It is also necessary to understand why the magnesium was added to the reactions and why it is
important in a successful polymerase chain reaction. Magnesium, or some form of it
(commonly used MgCl2, or magnesium chloride) is necessary as a cofactor to the DNA
polymerase used in the reaction. It is not consumed in the reaction, but without it the reaction
will be unsuccessful. The phosphate backbone of DNA has a negative charge to it, and thus
the positive charge of MgCl2 blocks this negative charge and allows for the DNA polymerase
to bind to the primers. Without this charge blockage, the polymerase would be unable to bind
and thus the replication process would fail.
The type of polymerase was also a major factor in the success of the PCR. It was found that
the polymerase from the 5 Prime PCR Extender System was successful. This more-expensive
DNA polymerase is marketed as having an additional component that increases accuracy of
the reaction and the proofreading capability. The buffers, both tuning and high fidelity, also
add to the success of the reaction by better maintaining pH balance at high temperatures, thus
reducing the possibility of DNA degradation at high temperatures.
One other point of discussion that was discussed in the Methods and Materials section was the
plasmid used for experimentation. pET28 is the vector used, and it was chosen for a few
reasons. The first is because of the presence of the Kan resistance factor, which is the
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antibiotic resistance factor that is necessary for growth when plated. The second reason is
because of the NdeI forward restriction site and XhoI reverse restriction site. These were
easily engineered into the forward and reverse primers to allow for easy ligation. Finally, the
vector has six histidines that are specifically engineered for easier post-transformation cleanup of the vector.
Finally, a discussion of how a ligation was deemed unsuccessful is necessary. This was
determined when no colonies were found on the media plate the next day, thus confirming
that no vectors were able to survive the conditions (they would have survived and formed
colonies had the PCR insert successfully ligated into the vector). The ligation process was
unsuccessfully attempted four trials; however it could not be determined why the ligation was
not working. Finally, it was determined that instead of performing a less-accurate double cut
of the vector; both cuts on the vector would be performed separately, thus ensuring 100%
accuracy. The final reactions where individual restriction site cuts were made finally yielded
success.
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Appendix A – Gel Electrophoresis Output of PCR with AccuTaq Polymerase

1 2

First gel electrophoresis output with lane products as follows:
1. 1 kb GeneRuler
2. Product of PCR using AccuTaq Polymerase
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Appendix B – Gel Electrophoresis of PCR with AccuTaq Polymerase with Additional MgCl2

1 2 34 5 6

The second gel electrophoresis output with lane products as follows:
1. GeneRuler 1 kb ladder
2. Product of PCR with additional 0.5 µL of MgCl2
3. Product of PCR with additional 1 µL of MgCl2
4. Product of PCR with additional 1.5 µL of MgCl2
5. Product of PCR with additional 2 µL of MgCl2
6. Genomic DNA Cd630
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Appendix C – Gel Electrophoresis of PCR using 5 Prime PCR Extender System

1 2 3 4 5

The third gel electrophoresis output with lane products as follows:
1. GeneRuler 1 kb ladder
2. Tuning Buffer with Mg with 1.25 µL of genomic DNA CD630
3. Tuning Buffer with Mg with 2.5 µL of genomic DNA CD630
4. High Fidelity Buffer with Mg with 1.25 µL of genomic DNA CD630
5. High Fidelity Buffer with Mg with 2.5 µL of genomic DNA CD630
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Appendix D – Forward Sequence of Successful Ligation Compared to Known CD1034
Sequence using Primer Complementary to the T7 Promotor on pET28
Forward Sequence – T7 Promoter Primer
>lcl|43923
Length=975
Score = 1504 bits (814), Expect = 0.0
Identities = 816/817 (99%), Gaps = 0/817 (0%)
Strand=Plus/Plus
Query

87

Sbjct

1

Query

147

Sbjct

61

Query

207

Sbjct

121

Query

267

Sbjct

181

Query

327

Sbjct

241

Query

387

Sbjct

301

Query

447

Sbjct

361

Query

507

Sbjct

421

Query

567

Sbjct

481

Query

627

Sbjct

541

Query

687

Sbjct

601

Query

747

Sbjct

661

Query

807

Sbjct

721

Query

867

Sbjct

781

ATGGCTAGAAAATTAATAAAAAATTTGGGTAAAAGTAAAAGTGTAAAGAGAGTGAAACTT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATGGCTAGAAAATTAATAAAAAATTTGGGTAAAAGTAAAAGTGTAAAGAGAGTGAAACTT

146
60

TTATTTAAGAAGATTTTTATTACTGTATTCATAGTAGCAAGTATAGTTGCTATTTTTAAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTATTTAAGAAGATTTTTATTACTGTATTCATAGTAGCAAGTATAGTTGCTATTTTTAAT

206

ATAACGAAATATTTTGAGGAATTATACAAAGTAAGGGATTTAAAAAGTACTAAAATTGAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATAACGAAATATTTTGAGGAATTATACAAAGTAAGGGATTTAAAAAGTACTAAAATTGAA

266

TACTATATGGATGTGGCTGATGAAGCAGGAGATGGAAAGGTCCAATTAAGTTGGAAGGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TACTATATGGATGTGGCTGATGAAGCAGGAGATGGAAAGGTCCAATTAAGTTGGAAGGCC

326

TTACTTGCTATAGACATGGTAATACATGATGAAGATTTAAGTAATATAAAAAAGAAAGAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTACTTGCTATAGACATGGTAATACATGATGAAGATTTAAGTAATATAAAAAAGAAAGAC

386

ACATTGGATATAGGGGAAAAGTTTATAGTAGAAGATAAAAATGATAAAGGCGAAAAGGTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACATTGGATATAGGGGAAAAGTTTATAGTAGAAGATAAAAATGATAAAGGCGAAAAGGTG

446

TATAAGGTAAAAAAGTTTAATAAAGTATTAAGCGAATTGAAATTTGACTCTTCTCAAAAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TATAAGGTAAAAAAGTTTAATAAAGTATTAAGCGAATTGAAATTTGACTCTTCTCAAAAA

506

AGTAGAGCAAGAAAATACATGAAAGATTTAGAATACACATACCTTGGAAATAAACAATTA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGTAGAGCAAGAAAATACATGAAAGATTTAGAATACACATACCTTGGAAATAAACAATTA

566

GATAGTAGTGATGAAAAAATTAAATTTATAAAGAAGTTAGAAGACTCAGCTATAAGAGAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GATAGTAGTGATGAAAAAATTAAATTTATAAAGAAGTTAGAAGACTCAGCTATAAGAGAA

626

TATATTGATTATGGAATATTGCCCTCTATAACAATTGGACAAGCTATATTAGAATCTGGT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TATATTGATTATGGAATATTGCCCTCTATAACAATTGGACAAGCTATATTAGAATCTGGT

686

TGGGGAAATTCTAAACTTACAAAACAGAGTAATAATTTATTTGGTATAAAAGCAGATAAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TGGGGAAATTCTAAACTTACAAAACAGAGTAATAATTTATTTGGTATAAAAGCAGATAAA

746

GCATGGAAAGGAAAAAGTGTAGAAATTTCAACTTCAGAGCATTATAATGAAAAAATTGTT
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCATGGAAAGGAAAAAGTGTAGAAATTTCAACTTCAGAGCATTATAATGAAAAAATTGTA

806

GCTAGTTTTAGGTCGTATAATTCATTACAAGATTCTGTCAAAGACCACAGTTTATTTTTA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCTAGTTTTAGGTCGTATAATTCATTACAAGATTCTGTCAAAGACCACAGTTTATTTTTA

866

ATTAATAATAAAAGATATAGAAAACATGGGTTGTTTG
|||||||||||||||||||||||||||||||||||||
ATTAATAATAAAAGATATAGAAAACATGGGTTGTTTG
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Appendix E –Reverse Sequence of Successful Ligation Compared to Known CD1034
Sequence using Primer Complementary to the Polymerase Termination Sequence on pET28
Reverse Complement – T7 Terminator Primer
>lcl|56645
Length=975
Score = 1676 bits (907), Expect = 0.0
Identities = 913/916 (99%), Gaps = 1/916 (0%)
Strand=Plus/Minus
Query

47

Sbjct

975

Query

107

Sbjct

915

Query

167

Sbjct

855

Query

227

Sbjct

795

Query

287

Sbjct

735

Query

347

Sbjct

675

Query

407

Sbjct

615

Query

467

Sbjct

555

Query

527

Sbjct

495

Query

587

Sbjct

435

Query

647

Sbjct

375

Query

707

Sbjct

315

Query

767

Sbjct

255

Query

827

Sbjct

195

TTATTTTGTCTCAACTTTATTATCTATCAATTGCAAATTATAACTCCTAATAACATCTAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTATTTTGTCTCAACTTTATTATCTATCAATTGCAAATTATAACTCCTAATAACATCTAT

106

TAATAGCTCTGCATATATACGATTTCCTTTTTTATCTTCTGCTGTACTATATCCTGCATT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TAATAGCTCTGCATATATACGATTTCCTTTTTTATCTTCTGCTGTACTATATCCTGCATT

166

TTCTAATGCTTGAGCTTGACTAATATAATCTTTTGCCTCAAACAACCCATGTTTTCTATA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTCTAATGCTTGAGCTTGACTAATATAATCTTTTGCCTCAAACAACCCATGTTTTCTATA

226

TCTTTTATTATTAATTAAAAATAAACTGTGGTCTTTGACAGAATCTTGTAATGAATTATA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TCTTTTATTATTAATTAAAAATAAACTGTGGTCTTTGACAGAATCTTGTAATGAATTATA

286

CGACCTAAAACTAGCAACAATTTTTTCATTATAATGCTCTGAAGTTGAAATTTCTACACT
||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
CGACCTAAAACTAGCTACAATTTTTTCATTATAATGCTCTGAAGTTGAAATTTCTACACT

346

TTTTCCTTTCCATGCTTTATCTGCTTTTATACCAAATAAATTATTACTCTGTTTTGTAAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTTTCCTTTCCATGCTTTATCTGCTTTTATACCAAATAAATTATTACTCTGTTTTGTAAG

406

TTTAGAATTTCCCCAACCAGATTCTAATATAGCTTGTCCAATTGTTATAGAGGGCAATAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTTAGAATTTCCCCAACCAGATTCTAATATAGCTTGTCCAATTGTTATAGAGGGCAATAT

466

TCCATAATCAATATATTCTCTTATAGCTGAGTCTTCTAACTTCTTTATAAATTTAATTTT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TCCATAATCAATATATTCTCTTATAGCTGAGTCTTCTAACTTCTTTATAAATTTAATTTT

526

TTCATCACTACTATCTAATTGTTTATTTCCAAGGTATGTGTATTCTAAATCTTTCATGTA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTCATCACTACTATCTAATTGTTTATTTCCAAGGTATGTGTATTCTAAATCTTTCATGTA

586

TTTTCTTGCTCTACTTTTTTGAGAAGAGTCAAATTTCAATTCGCTTAATACTTTATTAAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTTTCTTGCTCTACTTTTTTGAGAAGAGTCAAATTTCAATTCGCTTAATACTTTATTAAA

646

CTTTTTTACCTTATACACCTTTTCGCCTTTATCATTTTTATCTTCTACTATAAACTTTTC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTTTTTTACCTTATACACCTTTTCGCCTTTATCATTTTTATCTTCTACTATAAACTTTTC

706

CCCTATATCCAATGTGTCTTTCTTTTTTATATTACTTAAATCTTCATCATGTATTACCAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CCCTATATCCAATGTGTCTTTCTTTTTTATATTACTTAAATCTTCATCATGTATTACCAT

766

GTCTATAGCAAGTAANGCCTTCCAACTTAATTGGACCTTTCCATCTCCTGCTTCATCAGC
||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
GTCTATAGCAAGTAAGGCCTTCCAACTTAATTGGACCTTTCCATCTCCTGCTTCATCAGC

826

CACATCCATATAGTATTCAATTTTAGTACTTTTTAAATCCCTTACTTTGTATAATTCCTC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CACATCCATATAGTATTCAATTTTAGTACTTTTTAAATCCCTTACTTTGTATAATTCCTC

886
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